Tests WU-CART-007 cell therapy in relapsed T-cell leukemia and lymphoma
Tests WU-CART-007, an immune cell treatment, in people with returned T-cell leukemia or lymphoma.
Plain-language title generated from the registry record
Registry title: A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Key facts
- Where
- Melbourne, AustraliaSee the 2 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma whose disease came back, did not respond to treatment, or is still detectable (MRD positive).
- Age
- 6 months or older
- Sex
- All sexes can join.
- Disease stage
- T-ALL or T-LBL as defined by the World Health Organization (WHO), either relapsed, refractory, or MRD positive.
- Earlier treatment
- People who had any earlier anti-CD7 therapy cannot join.
Main reasons for not taking part
- Earlier treatment with any anti-CD7 therapy
- Decompensated hemolytic anemia
- Grade 2 to 4 acute or extensive chronic GvHD needing systemic immunosuppression
Read by machine on 9 November 2026.
Where in Australia
- Peter Mac Callum Cancer InstituteMelbourne, AustraliaTaking people
- Royal Children's MelbourneMelbourne, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Allotera Therapeutics
- Trial code
- NCT06514794
- Record updated
- 28 September 2026
- Original description
The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative responseRead full original descriptionShow less
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-RRex)
The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response
Inclusion: Disease Criteria: Evidence of T-ALL or T-LBL, as defined by World Health Organization (WHO) classification, and either relapse/refractory or MRD positive; Age: Lower age limit of ≥ 6 months; adequate organ function; Eastern Cooperative Oncology Group (ECOG) 0 or 1/Karnofsky Performance Status 70 and above at Screening.
Exclusion: Prior treatment with any anti-CD7 therapy; Presence of Grade 2 to 4 acute or extensive chronic GvHD requiring systemic immunosuppression. Grade 1 GvHD not requiring immunosuppression or Grade 2 skin GvHD if treated with topical therapy only are acceptable; Patients with decompensated hemolytic anemia.